clinical trial · NCT05554302
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Baptist Health South Florida·phase2·recruiting·n = 20
Brain MetastasesBrain Cancer18F-Fluciclovine
brief summary
This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.
started
Jan 10, 2023
primary completion
Jan 1, 2030
completion
Jan 1, 2030
last updated
Dec 1, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol